Editorial Videos

Lynlee Brown, partner at EY, discusses the impacts that the tariffs have across various regions.

Chris Springate, CEO, ARC Medical, discusses how postoperative adhesions continue to cause chronic pain, infertility, and life-threatening complications—despite advances in surgical techniques and often going undiagnosed for years.

Arda Ural explains how the tariffs will impact profit margins and potentially cause drug shortages.

Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.

Lynlee Brown discusses the decisions that companies must make to adjust to the tariffs while also ensuring the ongoing innovation continues.

Ted Sweetser discusses turning information into usable datasets and pulling insights from them.

Nigel McCracken, chief operating officer, Virax Biolabs explains how the ViraxImmune PAIS assay uses T cell responses and cytokine levels to detect immune dysfunction and identify viral triggers of chronic inflammation.

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Ted Sweetser discusses how the technology is providing greater insight into how marketing materials are being viewed.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity in terms of patient populations and underlying biological mechanisms.

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.

Ted Sweetser discusses how the technology is expanding the amount of content that can be created.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year.

Nigel McCracken, chief operating officer, Virax Biolabs, discusses results from new data on the role of T cell dysfunction in post-acute infection syndromes.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explains how Juvena plans to differentiate JUV-112 from other obesity therapeutics targeting adipose tissue.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" mentioned in their pipeline regarding their obesity (muscle target) program may impact the development timeline or potential partnerships for the program.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

Davidi Vortman, CEO, UltraSight, discusses how AI-powered heart scan technology can help high-risk cardiovascular disease patients.

LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses how Takeda will ensure that diversity and inclusion remain a priority in its clinical trials moving forward.

Amy Hessels, Bayer‘s vice president of marketing, talks about how to engage younger demographics and how the Your Decision campaign contributes to broader conversations about women's reproductive autonomy and healthcare access.

LaShell Robinson, head of global feasibility and trial equity at Takeda, identifies some of the key barriers in achieving representative clinical trials for psoriasis, and how they are overcoming them.

Amy Hessels, vice president of marketing, Bayer, discusses how its Your Decision campaign tackles misinformation about reproductive health by providing the information to empower women to discuss options with healthcare providers.

LaShell Robinson, head of global feasibility and trial equity at Takeda, talks about Takeda's aims to expand its efforts globally by adapting strategies to regional needs.

LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses strategies to address underrepresentation in clinical trials, particularly in phase III psoriasis trials.

Marcel Botha, CEO of 10XBeta, identifies the most significant technological innovations in medical device manufacturing that will be crucial for future pandemic preparedness and supply chain stability.

Matthew Yelovich, partner at Cleary Gottlieb, discusses his transition in late-2024 from working as a federal prosecutor to a role at Cleary Gottlieb, as well as how he sees the intersection of technology and law evolving in the Bay Area.

Marcel Botha, CEO of 10XBeta, explore the role collaboration between private industry, government agencies, and research institutions plays in strengthening pandemic preparedness and ensuring medical device resiliency.

Matthew Yelovich, partner at Cleary Gottlieb, discusses some of the broader implications for corporate governance and accountability the Theranos case highlights.

Marcel Botha, CEO of 10XBeta, discusses lessons from The Spiro Wave project that can be applied in creating more agile and responsive systems for future public health emergencies.

Matthew Yelovich, partner at Cleary Gottlieb, discusses the appeals of Elizabeth Holmes and Ramesh "Sunny" Balwani and the Ninth Circuit's recent affirmation of their convictions.